CSL (OTCMKTS:CSLLY) Shares Gap Down – What’s Next?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) gapped down prior to trading on Wednesday . The stock had previously closed at $64.40, but opened at $61.50. CSL shares last traded at $63.1650, with a volume of 4,939 shares traded.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Royal Bank Of Canada raised shares of CSL from a “hold” rating to a “moderate buy” rating in a report on Monday, January 19th. Zacks Research raised shares of CSL from a “strong sell” rating to a “hold” rating in a report on Monday, December 29th. Finally, Canaccord Genuity Group upgraded shares of CSL from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, CSL has an average rating of “Buy”.

CSL Stock Down 2.4%

The firm has a 50-day moving average price of $59.29 and a 200 day moving average price of $67.29. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.46 and a quick ratio of 1.12.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.